In this context, it is important to note, that the HLA-restricted target-recognition through the TCR remained a prominent hurdle for T cell-based therapies due to prominent tumor escape mechanisms, such as MHC downregulation [84,90,91,92,93,94,95]. The gene discussed is HLA-C; the disease is neoplasm.